Versus Systems Inc (VS) Stock News

CVS Health demonstrates attractive valuation and improving business performance, with Aetna's margin recovery gaining momentum and pharmacy segment showing strong prescription volume growth. However, 340B program pressures and expected Caremark membership declines pose near-term challenges. The stock trades at a discount to peers and has outperformed its industry, though technical indicators suggest weaker momentum.

Novartis received FDA approval for Rhapsido (remibrutinib) for symptomatic dermographism (SD), making it the only prescription treatment approved for both CSU and SD, the two most common forms of chronic hives. The approval was supported by phase III RemIND trial data showing 29.3% complete hive resolution at week 12 versus 14% for placebo. The company is also evaluating remibrutinib in multiple sclerosis, hidradenitis suppurativa, and food allergy. However, Novartis faces pipeline setbacks with failed trials for pelacarsen and del-desiran, and generic competition pressuring blockbuster drugs.

CVS Health is rated Zacks Rank #3 (Hold) with mixed signals. While the stock has underperformed the S&P 500 by 11.4% over the past month, the company demonstrates strong fundamentals including consistent earnings and revenue beat history, solid revenue growth projections, and attractive valuation metrics with an A grade on the Value Style Score. However, recent earnings estimate revisions have been slightly negative, suggesting the stock may perform in line with the broader market in the near term.

Vistra Corp. (VST) has attracted investor attention recently. While the company shows strong earnings growth projections (+71.9% for current fiscal year) and revenue growth (+27.4% for current fiscal year), it received a Zacks Rank #4 (Sell) rating. The stock has underperformed the S&P 500 over the past month (-3% vs +0.8%), and trades at par valuation with peers. Recent earnings surprised positively on EPS but missed significantly on revenue expectations.

Vistra Corp. (VST) declined 1.74% to $137.97, underperforming the S&P 500's 0.76% loss. Despite the recent dip, the stock has gained 0.99% over the past month. Analysts project strong earnings growth with EPS expected to increase 65.14% and revenue up 56.19% year-over-year. The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 15.53, trading at a discount to its industry average.

CVS Health stock declined 1.4% to $87.60, underperforming the broader market which gained 1.49%. The stock has fallen 4.49% over the past month. The company is expected to report flat EPS of $1.6 for the upcoming quarter with revenue projected at $105.04 billion (up 2.11% YoY). CVS holds a Zacks Rank #3 (Hold) rating and trades at a Forward P/E of 11.07, below its industry average of 17.31.

CVS Health closed down 1.17%, underperforming the S&P 500's 0.45% decline. Despite beating the Medical sector over the past month with a 1.64% gain, the company faces flat EPS projections for the upcoming quarter at $1.6, though full-year earnings are expected to grow 18.81%. CVS trades at a Forward P/E of 11.91, below its industry average, and holds a Zacks Rank #3 (Hold) rating.

CVS Health's Health Services segment demonstrated strong Q2 2026 performance with revenues rising 11.5% to $51.8B and adjusted operating income climbing 10%. Health Care Delivery revenues jumped nearly 23% driven by Oak Street Health, while Pharmacy Services benefited from favorable drug mix and strong new sales of $6B. The company maintained its full-year 2026 outlook despite 340B program adjustments.

Victoria's Secret (VSXY) shares have declined 10% despite strong Q2 results showing 9% comparable sales growth, expanded margins, and positive customer trends. However, the stock trades above its historical valuation while facing headwinds from tariffs, transportation costs, and increased marketing spending. Analysts recommend a cautious approach, suggesting the pullback improves entry price but doesn't eliminate execution risks.

Kaplan Fox has filed a securities class action lawsuit against Microvast Holdings (MVST) on behalf of investors who suffered losses between April 1, 2025 and March 16, 2026. The lawsuit alleges that Microvast made false statements about its manufacturing expansion (Huzhou Phase 3.2) and profit margins, which were contradicted by a Grizzly Research report and subsequent company disclosures showing gross margins collapsed to 1% and revenue declined 15% year-over-year.

A securities class action lawsuit has been filed against Microvast Holdings, Inc. (NASDAQ: MVST) for allegedly making materially false and misleading statements regarding margin targets, inventory management issues, and delays in the Huzhou Phase 3.2 expansion. Investors who purchased MVST securities between April 1, 2025 and March 16, 2026 may be eligible for compensation. The lead plaintiff deadline is September 21, 2026.

CVS Health's Pharmacy & Consumer Wellness segment showed strong growth with operating income up 10.2% year-over-year to $1.48 billion in Q2 2026, supported by higher prescription volumes and improved margins. The company raised its 2026 operating income outlook for the segment by $220 million. CVS is expanding AI tools including Health100 and Claims Assist Manager to improve efficiency and customer service. However, reimbursement pressure, regulatory scrutiny, and insufficient Medicare Advantage payment updates remain key headwinds. With a discounted valuation (P/S of 0.29X vs. industry average 0.53X), Zacks recommends current holders maintain positions while prospective investors wait for a more favorable entry point.

A class action securities fraud lawsuit has been filed against Microvast Holdings, Inc. for allegedly making materially false statements about its business operations between April 1, 2025 and March 16, 2026. The company allegedly overstated production facility activity, margin targets, and the timeline for completing its Huzhou Phase 3.2 expansion. The stock declined significantly following multiple negative announcements, including a CFO departure and disappointing financial results showing gross margin collapse to 1%. Shareholders have until September 21, 2026 to file a lead plaintiff motion.

Rosen Law Firm is notifying investors in Microvast Holdings (MVST) and Avis Budget Group (CAR) about ongoing securities class action lawsuits. MVST investors who purchased between April 1, 2025 and March 16, 2026 may be entitled to compensation due to alleged false statements regarding margin targets and facility expansion delays. The lead plaintiff deadline for MVST is September 21, 2026. Similar class action proceedings are underway for CAR investors.

The article discusses various investment opportunities across sectors including robotics and AI, oil and natural gas, aerospace, employment trends, and biotech. It highlights earnings estimate increases for an oil and gas company, market cap movements for a space company, job growth in leisure and hospitality, and provides stock screening tools for investors seeking diversified exposure to emerging themes.

ViaSat reported mixed Q1 fiscal 2027 results with earnings beating consensus estimates but revenues missing expectations. The company posted a narrower net loss of $51.7 million due to reduced interest expense from debt repayment, though revenues declined to $1.16 billion from $1.17 billion. Management expects mid-single-digit revenue growth for fiscal 2027, with DAT segment growth anticipated in the mid-teens. Shares have underperformed the S&P 500 by 13.7% since the earnings report, and analyst estimates have trended downward by 13.33%.

Victoria's Secret reported Q2 2026 earnings of $0.95 per share, beating consensus estimates of $0.78 and representing a 21.8% surprise. Revenue of $1.61 billion slightly missed expectations. The stock has gained 56.6% year-to-date and holds a Zacks Rank #2 (Buy) rating. Meanwhile, peer Zumiez is expected to report a quarterly loss of $0.14 per share with declining revenues.

Rosen Law Firm announces class action securities lawsuits against Microvast Holdings, Inc. (MVST) and GPGI, Inc. (formerly CompoSecure, Inc.). The MVST lawsuit alleges defendants made false statements regarding profitability targets, manufacturing expansion capabilities, and vehicle launch timelines. Investors who suffered losses exceeding $100,000 during the relevant periods are encouraged to seek legal representation before the September 21, 2026 deadline for MVST and September 14, 2026 for GPGI.

Univest (UVSP), a Northeast-based finance company, is highlighted as an attractive dividend play for income investors. The company offers a 2.24% dividend yield with a 5.7% year-over-year increase in annualized dividends. With a low 27% payout ratio and solid earnings growth projected at 17.25% for 2026, UVSP carries a Zacks Rank #2 (Buy) rating, making it a compelling investment opportunity despite the typical challenges dividend stocks face during rising interest rate periods.

CVS Health generated $10.6B in YTD operating cash flow and raised its full-year outlook to at least $11.5B, ending Q2 with $2.7B in cash. The company maintains a leverage ratio of 3.5x and expects improvement as it prioritizes balance-sheet strengthening over share buybacks in 2026-2027. Peers Align Technology and Cardinal Health also demonstrate strong liquidity positions with active capital deployment strategies.

CVS Health stock rallied 3.4-3.7% on Tuesday following bullish commentary from Jefferies analyst Brian Tanquilut, who affirmed a buy rating with a $120 price target (28% upside). The analyst highlighted strong management guidance suggesting 2027 EPS of at least $8.44, upcoming share buybacks, and Aetna's successful turnaround with over $2 billion in year-over-year operating income growth. CVS has beaten expectations for four consecutive quarters and raised full-year guidance to $8.00 adjusted EPS (19% growth).

UnitedHealth Group (UNH) emerges as the stronger investment choice compared to CVS Health (CVS), driven by improving results across UnitedHealthcare and Optum divisions, strong operating cash flows, and more attractive valuation. While CVS shows progress with Aetna margin recovery and pharmacy momentum, it faces 2027 headwinds from Caremark's 340B business challenges and expected membership decline. UNH trades at a 35% discount to its historical valuation multiple and has delivered stronger six-month returns.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against three companies. Photronics (PLAB) faces allegations of false statements regarding its product pipeline and demand stability (deadline: September 4, 2026). Planet Fitness (PLNT) is accused of misrepresenting its Black Card price increase rollout and membership growth (deadline: September 14, 2026). Microvast (MVST) allegedly made false statements about gross margin targets and inventory management (deadline: September 21, 2026). Investors who suffered losses during the alleged fraud periods are encouraged to seek lead plaintiff status.

Rosen Law Firm reminds Microvast Holdings (MVST) investors of the September 21, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management issues, delays in customer vehicle rollouts, and the Huzhou Phase 3.2 expansion completion timeline.

Rosen Law Firm announces September 21, 2026 deadline for investors to join a securities class action lawsuit against Microvast Holdings, Inc. (MVST). The lawsuit alleges the company made false statements regarding profitability targets, manufacturing capabilities at its Huzhou facility, and inventory management issues, causing investor losses.

Rosen Law Firm is alerting investors in Microvast Holdings (MVST) about a securities class action lawsuit with a September 21, 2026 lead plaintiff deadline. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management, and delays in the Huzhou Phase 3.2 expansion, causing investor losses.

The article compares AbbVie and CVS Health as healthcare investment options in 2026. AbbVie, a biopharmaceutical company with a $438B market cap, is recommended as the better choice due to its focused growth trajectory, strong drug pipeline (Skyrizi and Rinvoq), and attractive dividend yield. CVS Health, a diversified healthcare provider with a $122B market cap managing 37 million medical members, is acknowledged as a turnaround story showing stabilization but is considered less compelling than AbbVie's growth prospects.

Rosen Law Firm is encouraging investors who purchased securities of Microvast Holdings (MVST) between April 1, 2025 and March 16, 2026 to join a class action lawsuit. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management, and delays in the Huzhou Phase 3.2 expansion. The lead plaintiff deadline is September 21, 2026. Similar class action notices are being issued for PROCEPT BioRobotics and TransMedics Group.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Microvast Holdings, with allegations that the company made false statements about margin targets and the Huzhou Phase 3.2 expansion completion timeline. The lead plaintiff deadline is September 21, 2026. Similar notices are being issued for Hub Group and Peabody Energy.

A class action lawsuit has been filed against Microvast Holdings, Inc. (NASDAQ: MVST) for alleged securities fraud. The complaint alleges that company executives made materially false and misleading statements regarding business operations, margin targets, and the Huzhou Phase 3.2 expansion timeline. The lawsuit covers investors who purchased Microvast securities between April 1, 2025 and March 16, 2026. The stock experienced significant declines following revelations of inventory issues, delayed production capacity expansion, and a sharp drop in gross margins from 36% to 1%.